20/20 Onsite

Delivering Mobile Ophthalmic Examinations for Clinical Trials

20/20 Onsite is a clinical trial solutions company specializing in quality ocular endpoint protection through its nationwide point-of-need fleet. By bringing advanced ophthalmic assessments directly to clinical trial participants—whether at sites, homes, or community locations—20/20 Onsite makes it easier for sponsors, CROs, and sites to collect critical data, reduce patient burden, and improve trial outcomes. 20/20 Onsite has supported over 45 clinical trials, served more than 85,000 patients, achieved 100% of screening timelines, and consistently delivered patient Net Promoter Scores (NPS) above 95.

www.2020onsite.com

FireCyte Therapeutics

FireCyte is developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye

www.firecyte.com

Valitor

Biopolymers to Engineer Superior Biopharmaceuticals

Valitor is developing a pipeline of biopharmaceuticals using a proprietary platform technology that originated at UC Berkeley. Their products are designed to achieve previously unattainable pharmacological properties, thereby overcoming key challenges for major market indications. By leveraging established clinical mechanisms of action, Valitor can substantially de-risk the development of best-in-class therapies.